drugset
Drugs / Etokimab
last change Oct 2020 re-read 9 days ago

Etokimab

also known as ANB-020

Monoclonal antibody targets IL33 via inhibition

Developed for
atopic eczema · chronic rhinosinusitis · food allergy
Investigated by
AnaptysBio, Inc.

Trials 4

today NCT03614923 · Ph 2 NCT03533751 · Ph 2 NCT03469934 · Ph 2 NCT02920021 · Ph 2
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03614923 Nov 2018 → Sep 2020 chronic rhinosinusitis AnaptysBio, Inc. Completed Missed primary
Phase 2 NCT03533751 Jun 2018 → Dec 2019 atopic eczema AnaptysBio, Inc. Completed Missed primary
Phase 2 NCT03469934 Nov 2017 → Oct 2018 — AnaptysBio, Inc. Completed Missed primary
Phase 2 NCT02920021 Jan 2017 → Mar 2018 food allergy AnaptysBio, Inc. Completed Missed primary

News releases announcing trial results or a regulatory action · 6

DateIssuerRelease
2020-08-10 AnaptysBio, Inc. Results AnaptysBio Reports Top-Line Data from Interim Analysis of ECLIPSE Phase 2 Clinical Trial of Etokimab in Chronic Rhinosinusitis with Nasal Polyps anaptysbio.com ↗
Etokimab q4w and q8w treatment arms failed to achieve NPS and SNOT-22 statistical significance over placebo at this week 8 interim analysis
2020-08-10 AnaptysBio, Inc. Results AnaptysBio Announces Second Quarter 2020 Financial Results and Provides Pipeline Updates anaptysbio.com ↗
Interim 8-Week Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Did Not Demonstrate Statistical Significance For Either Q4W or Q8W Versus Placebo
2019-11-08 AnaptysBio, Inc. Results AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint anaptysbio.com ↗
Each of the etokimab dosing arms failed to meet the primary endpoint of the trial, which was demonstration of statistically greater improvement in the Eczema Area and Severity Index (EASI) relative placebo at week 16.
2019-11-08 AnaptysBio, Inc. Results AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates anaptysbio.com ↗
Each of the etokimab dosing arms failed to meet the primary endpoint of the trial, which was demonstration of statistically greater improvement in the Eczema Area and Severity Index (EASI) relative placebo at week 16.
2019-06-05 AnaptysBio, Inc. Results AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma anaptysbio.com ↗
Single dose of etokimab resulted in rapid and sustained lung function improvement and ACQ-5 score reduction through at least Day 64
2018-09-24 AnaptysBio, Inc. Results AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma anaptysbio.com ↗
today announced positive topline proof-of-concept data for etokimab, its investigational anti-IL-33 therapeutic antibody, in an ongoing single dose Phase 2a clinical trial in adult patients with severe eosinophilic asthma.

All press releases naming this drug 6 releases

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Etokimab ClinicalTrials.gov intervention name — accepted as the source's own label NCT03469934 ↗
3

NCT03533751 ↗

NCT02920021 ↗

NCT03614923 ↗
Known as ANB-020 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297580 ↗
Action Inhibit “Etokimab, an anti-IL-33 biologic” PMID 31723064 ↗ Nov 2019
Modality Monoclonal antibody “Humanized monoclonal antibody, administered by intravenous infusion” NCT02920021 ↗
Route Intravenous “Humanized monoclonal antibody, administered by intravenous infusion” NCT02920021 ↗
Target IL33 “Etokimab, an anti-IL-33 biologic” PMID 31723064 ↗ Nov 2019